Sun Pharma expects normalisation of India business in FY'19

Sun Pharma MD Dilip Shanghvi said the government's enforced price cuts and policy changes are potential risk factors for the business.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news